Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026

Entrada Therapeutics, Inc.

2025-Q3 EPS reported -$2.53 revenue$24,122,000

Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.
Cash, cash equivalents & marketable securities of $326.8M extended runway into Q3 2027.
ELEVATE-44-201 cohort 1 data on track for Q2 2026; first patient dosed in ELEVATE-45-201 with cohort 1 data expected mid-2026.
Filed UK regulatory authorization for ENTR-601-50; plans to submit EU applications in H2 2026.
Vertex VX-670 (DM1) trial enrollment and dosing on track for completion in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.